Literature DB >> 12584030

Does serum cholesterol contribute to vertebral bone loss in postmenopausal women?

L B Tankó1, Y Z Bagger, S B Nielsen, C Christiansen.   

Abstract

Recent in vitro and animal studies suggest that cholesterol and its metabolites inhibit the functional activity of osteoblasts and thereby induce reduced bone mineralization. However, scant information is available on the clinical implication of these findings with special regard to postmenopausal bone loss. Therefore, the aim of the present study was to investigate cross-sectional and longitudinal associations between serum cholesterol, bone mineral density (BMD), and bone turnover in 340 postmenopausal women aged 50-75 years (mean 59 years), who were followed for 8.3 +/- 1.1 years. BMD in the lumbar spine, distal forearm, and total hip was measured by dual energy X-ray absorptiometry. Other study variables were physical measures, serum cholesterol, serum markers of bone turnover, and self-reported information on various risk factors for osteoporosis. At baseline, serum cholesterol showed significant negative correlation with BMD at the lumbar spine (r = -0.21, P < 0.0001) and distal forearm (r = -0.14, P = 0.013), but not at the hip. No associations of serum cholesterol with serum osteocalcin (r = 0.054, P = 0.317) and CTX (r = -0.027, P = 0.623) were, however, noted. After adjustment for age and BMI, the negative correlation remained significant at the lumbar spine (r = -0.16, P = 0.004), but not at the distal forearm (r = -0.018, P = 0.738). At the end of the 8-year follow-up, the correlation between serum cholesterol and spine BMD was not observed. Those with the largest increases in serum cholesterol, however, showed the greatest decreases in spine BMD independently of the changes in BMI (r = -0.16, P = 0.004). The correlation between the changes in serum cholesterol and the simultaneous changes in osteocalcin (r = 0.081, P = 0.140) and CTX (r = 0.042, P = 0.441) were statistically insignificant. Thus, our results suggest that the weak associations between spine BMD and serum cholesterol can be explained by the fact that both variables are simultaneously affected by estrogen deficiency rather than by a direct influence of serum cholesterol on osteoblast function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584030     DOI: 10.1016/s8756-3282(02)00918-3

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  37 in total

1.  The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors.

Authors:  Erik R Nelson; Carolyn D DuSell; Xiaojuan Wang; Matthew K Howe; Glenda Evans; Ryan D Michalek; Michihisa Umetani; Jeffrey C Rathmell; Sundeep Khosla; Diane Gesty-Palmer; Donald P McDonnell
Journal:  Endocrinology       Date:  2011-09-20       Impact factor: 4.736

2.  Effects of exercise on lipid metabolism and musculoskeletal fitness in female athletes.

Authors:  Kung-Tung Chen; Rong-Sen Yang
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

3.  New Clues that May Link Osteoporosis to the Circulating Lipid Profile.

Authors:  Catalina Poiana; Valentin Radoi; Mara Carsote; John P Bilezikian
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

Review 4.  Childhood obesity, bone development, and cardiometabolic risk factors.

Authors:  Norman K Pollock
Journal:  Mol Cell Endocrinol       Date:  2015-03-27       Impact factor: 4.102

5.  Utility of biochemical screening in the context of evaluating patients with a presumptive diagnosis of osteoporosis.

Authors:  C Rajeswaran; J Spencer; J H Barth; S M Orme
Journal:  Clin Rheumatol       Date:  2006-05-11       Impact factor: 2.980

Review 6.  27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.

Authors:  Sisi He; Erik R Nelson
Journal:  Maturitas       Date:  2017-07-31       Impact factor: 4.342

7.  Adolescent obesity, bone mass, and cardiometabolic risk factors.

Authors:  Norman K Pollock; Paul J Bernard; Bernard Gutin; Catherine L Davis; Haidong Zhu; Yanbin Dong
Journal:  J Pediatr       Date:  2011-01-13       Impact factor: 4.406

Review 8.  The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.

Authors:  Erik R Nelson; Suzanne E Wardell; Donald P McDonnell
Journal:  Bone       Date:  2012-11-17       Impact factor: 4.398

Review 9.  27-Hydroxycholesterol: the first identified endogenous SERM.

Authors:  Michihisa Umetani; Philip W Shaul
Journal:  Trends Endocrinol Metab       Date:  2011-02-23       Impact factor: 12.015

10.  Serum lipid profile: its relationship with osteoporotic vertebrae fractures and bone mineral density in Turkish postmenopausal women.

Authors:  Filiz Sivas; Ebru Alemdaroğlu; Eda Elverici; Tuba Kuluğ; Kürşat Ozoran
Journal:  Rheumatol Int       Date:  2008-11-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.